Prognostic value of T-cells between primary colorectal cancer (pCRC) and its paired synchronous and metachronous liver metastasis (LM) is underinvestigated and is the subject of the present study. We enrolled into this retrospective cohort study patients, who underwent resection of both pCRC and synchronous LM (N = 55) or metachronous LM (N = 44). After immunohistochemical staining for CD3+, CD8+, and CD45R0+ whole slides were scanned and T-cell densities were quantified using QuPath software in tumor center (TC), inner margin (IM), outer margin (OM), and peritumor zone (PT) of pCRC and LM. High densities of CD8+ T-cells in TC, OM and PT of synchronous LM were associated with longer disease-free survival (DFS). Greater densities of CD3+ T-cells in IM and PT and CD8+ T-cells in IM, OM and PT in synchronous LM over pCRC were associated with longer DFS. Greater densities of CD8+ T-cells in the TC and IM and CD3+ T-cells in the IM of pCRC were found in the metachronous over synchronous group. The first novel finding demonstrated that high density of CD8+ T cells in synchronous LM were associated with favorable outcome. The second finding of high CD8+ cell density in pCRC in metachronous over synchronous CRC may provide a mechanistic basis for the delay of metastatic spread. Both findings could be applied clinically with own reference values.

• MeSH
• CD8-pozitivní T-lymfocyty imunologie   MeSH
• dospělí MeSH
• kolorektální nádory * patologie   imunologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mnohočetné primární nádory patologie   imunologie   MeSH
• nádory jater * sekundární   imunologie   patologie   MeSH
• přežití bez známek nemoci MeSH
• prognóza MeSH
• retrospektivní studie MeSH
• sekundární malignity patologie   MeSH
• senioři MeSH
• T-lymfocyty imunologie   patologie   MeSH
• tumor infiltrující lymfocyty imunologie   patologie   MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

We analyzed mucormycosis data from the Zygomyco.net registry (2009-2022), encompassing cases from 16 countries. India, Russia and the Czech Republic provided the largest contributions. India reported the highest case number, consistent with its substantially higher incidence compared to that of high-income countries. Among the 382 patients with mucormycosis, 236 (61.8%) were male (male-to-female ratio 1.6). The median age was 48 years [interquartile range (IQR) 32-60]. There were 59 pediatric patients (median age ranging from < 1 month to 19 years). Diabetes mellitus type 2 was the most common underlying condition (39%), with significant geographic variation (> 70% of cases in India and Iran but only 6.9% in Europe). Hematologic malignancies (HM, 31.4%), the second most common underlying condition, were absent in India and Iran. The primary clinical presentations were rhino-orbito-cerebral mucormycosis (ROCM, 36.6%), pulmonary (33.2%) and cutaneous mucormycosis (17.5%). Patients with diabetes mellitus typically developed ROCM (55.9%), while pulmonary infections were more common in those with HM or hematopoietic cell transplantation (HCT) (47.5%, p < 0.001). Rhizopus was the leading fungal genus (58%), followed by Lichtheimia (13.7%) and Mucor (7%), with regional variations. Pulmonary infections in HM patients were linked to L. corymbifera and R. microsporus, while Apophysomyces spp. and Saksenaea spp. were more frequent in Indian healthcare-associated cutaneous cases. Concomitant infections were observed in 8.7% of patients with HM, complicating diagnosis and treatment. In most of them (57.1%), Aspergillus spp. was involved. Improved diagnostic practices, including direct microscopy and cultures, showed higher positivity rates, although PCR remained underutilized. Antifungal therapy, primarily with an amphotericin B formulation, combined with surgery, was the most common therapeutic approach. Overall mortality was high (47.8%), particularly in disseminated or advanced ROCM cases. Multivariable analysis identified older age, advanced ROCM, and HM/HCT as independent mortality risk factors (p < 0.05); whereas localized sinusitis and combined medical and surgical therapy were independently associated with improved outcomes (p < 0.006). This study underscores regional disparities in the mucormycosis epidemiology and species distribution. Improved early detection is needed, particularly in immunocompromised populations with HM. Enhanced surveillance and tailored public health strategies are crucial to address this ongoing global health threat.

• MeSH
• celosvětové zdraví MeSH
• dítě MeSH
• dospělí MeSH
• incidence MeSH
• kojenec MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• mukormykóza * epidemiologie   mikrobiologie   farmakoterapie   MeSH
• novorozenec MeSH
• předškolní dítě MeSH
• registrace * MeSH
• Check Tag
• dítě MeSH
• dospělí MeSH
• kojenec MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• novorozenec MeSH
• předškolní dítě MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Geografické názvy
• Evropa MeSH

Úvod: Karcinóm hrtana je celosvetovo jedenástou najčastejšou formou rakoviny u mužov, a zároveň druhou najčastejšou formou malignity hlavy a krku. Štúdia sa zaoberá 10-ročnou retrospektívnou analýzou klinických charakteristík a postupov liečby u pacientov s karcinómom hrtana. Materiál a metódy: Analyzované boli dáta pacientov s karcinómom hrtana, ktorí boli diagnostikovaní a liečení na Klinike otorinolaryngológie, chirurgie hlavy a krku LF UK a UN Bratislava v rokoch 2012 až 2021. Zamerali sme sa na hodnotenie z hľadiska základných charakteristík, lokalizácie a rozsahu tumoru a typu liečebného výkonu. V ďalšej časti sme analyzovali súbor pacientov z hľadiska absolvovanej liečebnej modality a kontrolných endoskopií. Výsledky: Do súboru bolo zaradených spolu 427 pacientov, z toho bolo 390 mužov (91 %) a 37 žien (9 %), priemerný vek pacientov bol 63,6 rokov. Z hľadiska lokalizácie tumoru boli v najväčšej miere zastúpené glotické nádory (n = 256), najmenej bolo subglotických (n = 10). Transorálne chirurgické výkony boli vykonané častejšie ako chirurgické výkony z vonkajšieho prístupu. Najčastejším typom chordektómie bola chordektómia typ III. Parciálne resekcie z vonkajšieho prístupu boli realizované len do roku 2016, potom sa už nevykonávali. Počty laryngektómií boli v analyzovaných rokoch vyrovnané, laryngofaryngektómie neboli veľmi časté, v našom súbore ich bolo len 6. Až 93 % výkonov z vonkajšieho prístupu bolo kombinovaných s krčnou disekciou, 7 % výkonov bolo samostatných. Z kontrolných endoskopií bola najčastejším výkonom prvá kontrolná endoskopia. Primárnu nechirurgickú liečbu podstúpilo 111 pacientov z celého súboru. Záver: Zastúpenie mužov bolo výrazne vyššie ako zastúpenie žien. Najviac laryngeálnych tumorov bolo lokalizovaných v oblasti glotis. V analyzovanej skupine prevažovala transorálna chirurgická liečba, najčastejšia bola chordektómia typ III. Prevažná väčšina liečebných chirurgických výkonov z vonkajšieho prístupu bola kombinovaná s krčnou disekciou.

Introduction: Laryngeal carcinoma is the eleventh most common form of cancer in men worldwide, and at the same time the second most common form of head and neck malignancy. The study deals with a 10-year retrospective analysis of clinical characteristics and treatment procedures in patients with laryngeal carcinoma. Materials and methods: We analyzed the data of patients with laryngeal cancer who were diagnosed and treated at the Department of Otorhinolaryngology, Head and Neck Surgery of the Faculty of Medicine, UK and UN in Bratislava between 2012 and 2021. We focused on the evaluation in terms of basic characteristics, localization and extent of the tumor, and type of treatment. In the next part, we analyzed a set of patients in terms of the completed treatment modality and control endoscopies. Results: A total of 427 patients were included in the group, of which 390 were men (91%) and 37 were women (9%), and the average age of the patients was 63.6 years. In terms of tumor localization, glottic tumors were the most represented (N = 256) and subglottic tumors were the least represented (N = 10). Transoral surgical procedures were performed more often than surgical procedures from the external approach. The most common type of chordectomy was type III chordectomy. Partial resections from the external approach were performed only until 2016, after which they were no longer performed. The number of laryngectomies was equal in the analyzed years, laryngopharyngectomies were not very frequent, and only 6 of them were performed in our group. Up to 93% of procedures from the external approach were combined with neck dissection, while 7% of the procedures were separate. Of the control endoscopies, the most common procedure was the first control endoscopy. Then, 111 patients from the entire group underwent primary non-surgical treatment. Conclusion: The representation of men was higher than the representation of women. Most laryngeal tumors were located in the glottis area. Transoral surgical treatment prevailed in the analyzed group, with chordectomy type III being the most common. The vast majority of curative surgical procedures from the external approach were combined with neck dissection.

• MeSH
• lidé MeSH
• nádory hrtanu * chirurgie   diagnóza   MeSH
• retrospektivní studie MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH

OBJECTIVES: Patients with non-muscle invasive bladder cancer (NMIBC) face a high risk of recurrence and progression after transurethral resection, making adjuvant therapies necessary. Intravesical device-assisted therapies, such as radiofrequency-induced thermochemotherapy (RITE), have shown promise in enhancing the effectiveness of intravesical chemotherapies. This study aimed to evaluate oncological outcomes in patients with NMIBC treated with RITE in a real-world setting, encompassing those unresponsive to prior Bacillus Calmette-Guérin (BCG) or intravesical chemotherapy, as well as those who declined or were ineligible for BCG or radical cystectomy (RC). METHODS: A retrospective multicenter analysis of patients treated with RITE for NMIBC between 2015 and 2024 was performed. Co-primary endpoints of the study were intravesical recurrence free survival (RFS) and high-grade intravesical recurrence free survival (HG-RFS). Secondary endpoints included radical cystectomy-free survival (RC-FS), overall survival (OS), cancer-specific survival (CSS), and adverse events (AEs). RESULTS: Fifty-nine consecutive patients were included in the final analyses. Overall, 12 (20%) and 45 (76%) patients failed previous intravesical chemotherapy, and immunotherapy with BCG, respectively. The 24-months RFS and HG-RFS following RITE were 68.6% (95% CI: 0.568, 0.828) and 74.8% (95% CI: 0.632, 0.885). RC-FS at 24 months was 93.8% (95% CI: 0.872, 1.000). The OS probability at 24 months was 91%, with a CSS of 97.8%. Most common AEs were dysuria and urgency in 27 (45.7%) patients, treatment limiting bladder spasms in 11 (19%) patients, low bladder compliance in 11 (19%) patients and urethral strictures in 5 (8%) patients. CONCLUSION: In our analyses, RITE resulted in notable antitumor activity and allows for the avoidance of more aggressive and quality-of-life-limiting therapies, such as radical cystectomy. RITE might be considered as a second-line bladder-sparing option in patients failing previous intravesical therapies. Long-term follow-up and larger-scale data are required to validate our findings.

• MeSH
• cystektomie MeSH
• indukovaná hypertermie * metody   MeSH
• invazivní růst nádoru MeSH
• lidé středního věku MeSH
• lidé MeSH
• nádory močového měchýře neinvadující svalovinu MeSH
• nádory močového měchýře * terapie   patologie   mortalita   MeSH
• retrospektivní studie MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH

IMPORTANCE: The current standard-of-care salvage therapy in relapsed/refractory classic Hodgkin lymphoma (cHL) includes consolidation high-dose chemotherapy (HDCT)/autologous stem cell transplant (aSCT). OBJECTIVE: To investigate whether presalvage risk factors and fludeoxyglucose-18 (FDG) positron emission tomography (PET) response to reinduction chemotherapy can guide escalation or de-escalation between HDCT/aSCT or transplant-free consolidation with radiotherapy to minimize toxic effects while maintaining high cure rates. DESIGN, SETTING, AND PARTICIPANTS: EuroNet-PHL-R1 was a nonrandomized clinical trial that enrolled patients younger than 18 years with first relapsed/refractory cHL across 68 sites in 13 countries in Europe between January 2007 and January 2013. Data were analyzed between September 2022 and July 2024. INTERVENTION: Reinduction chemotherapy consisted of alternating IEP (ifosfamide, etoposide, prednisolone) and ABVD (adriamycin, bleomycin, vinblastine, dacarbazine). Patients with low-risk disease (late relapse after 2 cycles of first-line chemotherapy and any relapse with an adequate response after 1 IEP/ABVD defined as complete metabolic response on FDG-PET and at least 50% volume reduction) received a second IEP/ABVD cycle and radiotherapy (RT) to all sites involved at relapse. Patients with high-risk disease (all primary progressions and relapses with inadequate response after 1 IEP/ABVD cycle) received a second IEP/ABVD cycle plus HDCT/aSCT with or without RT. MAIN OUTCOMES AND MEASURES: The primary end point was 5-year event-free survival. Secondary end points were overall survival (OS) and progression-free survival (PFS). PFS was identical to event-free survival because no secondary cancers were observed. PFS data alone are presented for simplicity. RESULTS: Of 118 patients analyzed, 58 (49.2%) were female, and the median (IQR) age was 16.3 (14.5-17.6) years. The median (IQR) follow-up was 67.5 (58.5-77.0) months. The overall 5-year PFS was 71.3% (95% CI, 63.5%-80.1%), and OS was 82.7% (95% CI, 75.8%-90.1%). For patients in the low-risk group (n = 59), 41 received nontransplant salvage with a 5-year PFS of 89.7% (95% CI, 80.7%-99.8%) and OS of 97.4% (95% CI, 92.6%-100%). In contrast, 18 received HDCT/aSCT off protocol, with a 5-year PFS of 88.9% (95% CI, 75.5%-100%) and OS of 100%. All 59 patients with high-risk disease received HDCT/aSCT (and 23 received post-HDCT/aSCT RT) with a 5-year PFS of 53.3% (95% CI, 41.8%-67.9%) and OS of 66.5% (95% CI, 54.9%-80.5%). CONCLUSION AND RELEVANCE: In this nonrandomized clinical trial, FDG-PET response-guided salvage in relapsed cHL may identify patients in whom transplant-free salvage achieves excellent outcomes. HDCT/aSCT may be reserved for primary progression and relapsed cHL with inadequate response. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT00433459.

• MeSH
• autologní transplantace MeSH
• dítě MeSH
• etoposid terapeutické užití   aplikace a dávkování   MeSH
• Hodgkinova nemoc * terapie   farmakoterapie   patologie   MeSH
• lidé MeSH
• lokální recidiva nádoru MeSH
• mladiství MeSH
• pozitronová emisní tomografie MeSH
• protokoly protinádorové kombinované chemoterapie terapeutické užití   MeSH
• transplantace hematopoetických kmenových buněk MeSH
• záchranná terapie * MeSH
• Check Tag
• dítě MeSH
• lidé MeSH
• mladiství MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky, fáze III MeSH
• komentáře MeSH
• multicentrická studie MeSH

Většina nemocných s klasickým Hodgkinovým lymfomem je trvale vyléčena po první linii onkologické léčby. V případě relapsu či refrakterity je u mladších a chemosenzitivních případů stále indikována záchranná a vysokodávkovaná chemoterapie s autologní transplantací hemopoetických kmenových buněk. V případě selhání či nemožnosti provedení autologní transplantace je v další linii většinou podávána imunoterapie s využitím léčiv ze skupiny tzv. checkpoint inhibitorů. Po selhání imunoterapie je další terapeutická strategie obtížnou výzvou. Tato kazuistika popisuje průběh léčby primárně refrakterního Hodgkinova lymfomu, kdy po selhání konvenční léčby chemoterapií, radioterapií, ale i samotnou imunoterapií bylo nakonec dosaženo kompletní remise až pomocí kombinovaného protokolu imunoterapie pembrolizumab a chemoterapie GVD, obsahující gemcitabin, vinorelbin a liposomální doxorubicin. U pacientky byla následně úspěšně podána vysokodávkovaná chemoterapie s provedením autologní transplantace hematopoetických kmenových buněk a konsolidace brentuximab vedotinem s kurabilním záměrem.

Majority of patients with classic Hodgkin lymphoma are cured after the first line treatment. Salvage and high-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation is a standard of care for younger patients with chemo-sensitive relapsed or refractory Hodgkin lymphoma in the second line setting yet. If a patient is not indicated for transplantation or if it fails, immunotherapy with checkpoint inhibitors are usually given. When even immunotherapy fails, further treatment strategy is a difficult challenge. In our report, we describe a case of a patient with primary refractory classic Hodgkin lymphoma, and a treatment after failure of all of the treatment modalities mentioned above - chemotherapy, radiotherapy and immunotherapy as well. A complete remission was finally achieved using combined modality regimen of both; pembrolizumab immunotherapy and chemotherapy GVD containing gemcitabine, vinorelbine and liposomal doxorubicin. In a complete remission the patient finally could proceed to the high-dose chemotherapy followed by successful autologous stem-cell transplantation and brentuximab vedotin consolidation with curable intent.

• Klíčová slova
• pembrolizumab,
• MeSH
• brentuximab vedotin farmakologie   terapeutické užití   MeSH
• dospělí MeSH
• Hodgkinova nemoc * diagnóza   farmakoterapie   klasifikace   MeSH
• homologní transplantace klasifikace   metody   MeSH
• imunoterapie metody   MeSH
• inhibitory kontrolních bodů * farmakologie   klasifikace   terapeutické užití   MeSH
• lidé MeSH
• transplantace hematopoetických kmenových buněk metody   MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• ženské pohlaví MeSH
• Publikační typ
• kazuistiky MeSH

BACKGROUND: Immune checkpoint inhibitors (ICIs) are an important therapeutic pillar in metastatic urothelial carcinoma (mUC). The occurrence of immune-related adverse events (irAEs) appears to be associated with improved outcomes in observational studies. However, these associations are likely affected by immortal time bias and do not represent causal effects. The aim of this study was to assess the effect of irAEs on outcomes while correcting for immortal time bias, using target trial emulation (TTE). METHODS: TTE was contrasted to adjusted naïve and time-updated Cox models. We performed a multi-institutional retrospective study involving mUC patients under ICI. The primary objective was to assess the impact of irAEs on progression-free survival (PFS) and overall survival (OS). Secondary endpoints included the influence of irAEs on objective response rates (ORRs) to ICI and the influence of systemic corticosteroids on outcomes. RESULTS: Among 335 patients (median age: 69 yrs), 69.6% received ICI in the second line or further lines. During a median follow-up of 21.1 months, 122 (36.4%) patients developed irAEs of any grade (grade ≥ 3: 14.9%). Hazard ratios (HRs) for PFS ranged from 0.37 for naïve adjusted Cox model to 0.88 (95% confidence interval (CI), 0.59-1.30) with time-updated covariates, and from 0.41 to 1.10 (95% CI, 0.69-1.75) for OS. TTE accounting for immortal time bias yielded a HR of 1.02 (95% CI, 0.72-1.44) for PFS, and 0.90 (95% CI, 0.62-1.30) for OS. In contrast to the naïve Cox model (HR = 2.26, 95% CI 1.26-4.05), the presence of irAEs was no longer a predictive factor for improved ORR in time-updated Cox models (HR = 1.27, 95% CI 0.68-2.36) and TTE (HR = 1.43, 95% CI 0.89-2.29). In patients with irAEs, systemic corticosteroids did not negatively impact survival. CONCLUSION: Using TTE, we were able to show that the occurrence of irAEs is no longer associated with better survival or improved response rates to ICI in mUC patients, in contrast to the naïve analysis. These findings demonstrate that TTE is a suitable formal framework to avoid immortal time bias in studies with time-dependent non-interventional exposures.

• MeSH
• inhibitory kontrolních bodů * škodlivé účinky   terapeutické užití   MeSH
• karcinom z přechodných buněk farmakoterapie   mortalita   imunologie   MeSH
• lidé středního věku MeSH
• lidé MeSH
• metastázy nádorů MeSH
• nádory močového měchýře farmakoterapie   mortalita   imunologie   patologie   MeSH
• nežádoucí účinky léčiv etiologie   MeSH
• retrospektivní studie MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• urologické nádory farmakoterapie   mortalita   imunologie   patologie   MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH

The most important challenges in acute promyelocytic leukemia (APL) is preventing early death and reducing long-term events, such as second neoplasms (s-NPLs). We performed a retrospective analysis of 2670 unselected APL patients, treated with PETHEMA "chemotherapy based" and "chemotherapy free" protocols. Only de novo APL patients who achieved complete remission (CR) and completed the three consolidation cycles were enrolled into the analysis. Out of 2670 APL patients, there were 118 (4.4%) who developed s-NPLs with the median latency period (between first CR and diagnosis of s-NPL) of 48.0 months (range 2.8-231.1): 43.3 (range: 2.8-113.9) for s-MDS/AML and 61.7 (range: 7.1-231.1) for solid tumour. The 5-year CI of all s-NPLs was of 4.43% and 10 years of 7.92%. Among s-NPLs, there were 58 cases of s-MDS/AML, 3 cases of other hematological neoplasms, 57 solid tumours and 1 non-identified neoplasm. The most frequent solid tumour was colorectal, lung and breast cancer. Overall, the 2-year OS from diagnosis of s-NPLs was 40.6%, with a median OS of 11.1 months. Multivariate analysis identified age of 35 years (hazard ratio = 0.2584; p < 0.0001) as an independent prognostic factor for s-NPLs. There were no significant differences in CI of s-NPLs at 5 years between chemotherapy-based vs chemotherapy-free regimens (hazard ratio = 1.09; p = 0.932). Larger series with longer follow-up are required to confirm the potential impact of ATO+ATRA regimens to reduce the incidence of s-NPLs after front-line therapy for APL.

• MeSH
• akutní promyelocytární leukemie * diagnóza   farmakoterapie   epidemiologie   MeSH
• dospělí MeSH
• incidence MeSH
• lidé MeSH
• patologická kompletní odpověď MeSH
• protokoly protinádorové kombinované chemoterapie terapeutické užití   MeSH
• retrospektivní studie MeSH
• rizikové faktory MeSH
• sekundární malignity * farmakoterapie   MeSH
• tretinoin MeSH
• výsledek terapie MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• Publikační typ
• časopisecké články MeSH

BACKGROUND: A higher risk of secondary brain tumor, carotid stenosis, and stroke has been reported after conventional sella irradiation for pituitary neuroendocrine tumors (PitNET). Stereotactic radiosurgery (SRS), which is a more focused approach, is now increasingly used instead. The aim was to assess the risk of secondary brain tumor, carotid stenosis/occlusion, and stroke after SRS. METHODS: In this multicentric retrospective study, 2254 patients with PitNET were studied, 1377 in the exposed group, and 877 in the control group. RESULTS: There were 9840.1 patient-years at risk for the SRS and 5266.5 for the control group. The 15-year cumulative probability of secondary intracranial tumor was 2.3% (95% CI: 0.5%, 4.1%) for SRS and 3.7% (95% CI: 0%, 8.7%) for the control group (P = .6), with an incidence rate of 1.32 per 1000 and 0.95 per 1000, respectively. SRS was not associated with an increased risk of tumorigenesis when stratified by age (HR: 1.59 [95% CI: 0.57, 4.47], Pp = .38). The 15-year probability of new carotid stenosis/occlusion was 0.9% (95% CI: 0.2, 1.6) in the SRS and 2% (95% CI: 0, 4.4) in the control group (P = .8). The 15-year probability of stroke was 2.6% (95% CI: 0.6%, 4.6%) in the SRS and 11.1% (95% CI: 6%, 15.9%) in the control group (P < .001). In Cox multivariate analysis stratified by age, SRS (HR 1.85 [95% CI:0.64, 5.35], P = .26) was not associated with risk of new stroke. CONCLUSIONS: No increased risk of long-term secondary brain tumor, new stenosis or occlusion, and stroke was demonstrated in the SRS group compared to the control in this study with imaging surveillance.

• MeSH
• cévní mozková příhoda * etiologie   epidemiologie   MeSH
• dítě MeSH
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• nádory hypofýzy * epidemiologie   MeSH
• nádory mozku epidemiologie   etiologie   MeSH
• následné studie MeSH
• prognóza MeSH
• radiochirurgie * škodlivé účinky   MeSH
• retrospektivní studie MeSH
• rizikové faktory MeSH
• sekundární malignity etiologie   epidemiologie   patologie   MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• stenóza arteria carotis * etiologie   epidemiologie   MeSH
• Check Tag
• dítě MeSH
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH

BACKGROUND: Vitamin D deficiency associates with the risk of developing many diseases, including cancer. At the molecular level, vitamin D appears to have an antineoplastic effect. However, the role of vitamin D deficiency in cancer pathogenesis remains unelucidated and numerous studies have resulted in discordant results. This study aimed to determine whether vitamin D deficiency during melanoma diagnosis increases the risk of developing non-cutaneous second primary cancers (SPC). MATERIALS AND METHODS: A retrospective study on 663 patients diagnosed with melanoma between 1 January 2011 and 31 October 2022. The effect of each variable on the development of a subsequent non-cutaneous cancer was performed using Kaplan-Meier curves and differences were assessed by log-rank tests. Cox proportional hazard univariate and multivariate models were used to quantify the effect of each variable in the time to develop a non-cutaneous neoplasia. RESULTS: Out of 663 patients, 34 developed a non-cutaneous SPC. There was no statistically significant association between vitamin D levels and non-cutaneous SPC development (log-rank, p=0.761). Age>60 years, stage III/IV, and nodular melanoma subtype were significantly associated with the development of a SPC. After multivariate analysis, only age>60 years (HR 3.4; HR CI 95%: 1.5-7.6) and nodular melanoma subtype (HR 2.2; HR CI 95%: 1.0-4.8) were included in the final model. CONCLUSIONS: Our results suggest that vitamin D deficiency is not associated with an increased risk of developing non-cutaneous SPC in melanoma patients. However, age over 60 years and nodular melanoma subtype increase the risk for non-cutaneous SPC development.

• MeSH
• lidé středního věku MeSH
• lidé MeSH
• melanom * epidemiologie   etiologie   diagnóza   MeSH
• nádory kůže * etiologie   komplikace   MeSH
• nedostatek vitaminu D * komplikace   epidemiologie   MeSH
• retrospektivní studie MeSH
• sekundární malignity * epidemiologie   etiologie   MeSH
• vitamin D škodlivé účinky   MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• pozorovací studie MeSH